Immunogenicity of yeast-derived hepatitis B vaccines in young adults.
A study of the safety and immunogenicity of two different recombinant DNA yeast-derived hepatitis B vaccines was conducted in 90 young adults according to a 0-, 1-, and 6-month vaccination schedule. Preliminary results using the 20 micrograms SmithKline Biologicals or 10 micrograms Merck Sharp & Dohme recombinant yeast-derived hepatitis B vaccines indicate that both vaccines are clinically safe and immunogenic. Only minor side effects have thus far been reported. Seroconversion rates among vaccine recipients were 80% or greater after the first two injections with either vaccine, and 100% after the third dose of the SmithKline Biologicals recombinant DNA hepatitis B vaccine.
Bergamini
F
F
Istituto di Virologia dell'Università di Milano, Italy.
Zanetti
A
A
D000328:Adult; D000941:Antigens / Q000627:therapeutic use*; D004274:DNA, Recombinant / Q000276:immunology; D005260:Female; D006509:Hepatitis B / Q000517:prevention & control*; D006510:Hepatitis B Antibodies / Q000032:analysis*; D006801:Humans; D008297:Male; D012441:Saccharomyces cerevisiae / Q000235:genetics; D014611:Vaccination / Q000009:adverse effects; D014614:Vaccines, Synthetic / Q000009:adverse effects / Q000627:therapeutic use*
D000941:Antigens; D004274:DNA, Recombinant; D006510:Hepatitis B Antibodies; D014614:Vaccines, Synthetic